Authors: Carlo Pozzilli Luca Prosperini
Publish Date: 2008/08/09
Volume: 29, Issue: 2, Pages: 211-213
Abstract
Interferon beta IFNβ and glatiramer acetate GA showed a relevant impact in modifying the clinical course of relapsingremitting multiple sclerosis However not all treated patients experience a satisfied response to therapy in terms of suppression of relapse and slowing disability progressionAt the present time none of the proposed criteria of response to disease modifying therapies DMTs have been validated Clinical parameters such as relapse rate and disability progression assessing with EDSS scale may represent two useful indicators of therapeutic response but their value in predicting the longterm response to DMTs is weak
Keywords: